Search clinical trials for: Triple-negative Breast Cancer

Total 87967 results

Merck Sharp & Dohme LLC

Not yet recruiting

Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR

Triple-Negative Breast Cancer
Fudan University

Recruiting

LM-108 in Combination With PD-1 Based Treatment for Patients With Recurrent or Metastatic Triple - Negative Breast Cancer

TNBC - Triple-Negative Breast Cancer

China
Sichuan Baili Pharmaceutical Co., Ltd.
Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.

Not yet recruiting

A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer

Triple-Negative Breast Cancer

China
First Affiliated Hospital of Zhejiang University
Shanghai Longfine Biotechnology Co., Ltd.; TopAlliance

Not yet recruiting

A Study on the Efficacy and Safety of Oral All-trans Retinoic Acid Combined With Toripalimab in TNBC.

Triple-negative Breast Cancer

China
Wuhan Union Hospital, China

Recruiting

Cadonilimab Combined With Chemotherapy as First or Second Line Treatment in Recurrent or Metastatic Triple Negative Breast Cancer

Triple-negative Breast Cancer | Cadonilimab

China
Swiss Group for Clinical Cancer Research

Not yet recruiting

Intratumoral INT230-6 Followed by Neoadjuvant Immuno-chemotherapy in Patients With Early TNBC. INVINCIBLE-4-SAKK

Triple-negative Breast Cancer | TNBC - Triple-Negative Breast Cancer

Switzerland
Fudan University

Not yet recruiting

Inosine Reverse Chemo Resistance in Triple Negative Breast Cancer

Triple-negative Breast Cancer
Fudan University

Not yet recruiting

Dasatinib Combined With Quercetin to Reverse Chemo Resistance in Triple Negative Breast Cancer

Triple-negative Breast Cancer
The Netherlands Cancer Institute
Hoffmann-La Roche

Not yet recruiting

NOvel Immunotherapy Strategies for Advanced Triple Negative Breast Cancer (TNBC) Patients: TONIC-3 Trial (TONIC-3)

Metastatic Breast Cancer
Monopar Therapeutics

Recruiting

Diagnostic Efficacy and Dosimetry of MNPR-101-DFO*-89Zr in Patients With Solid Tumors

Gastric Cancer | Colorectal Cancer | Pancreatic Cancer | Ovarian Cancer | Lung Cancer | Bladder Cancer | Urothelial Carcinoma | Triple-negative Breast Cancer | Solid Tumor, Adult

Australia
Emory University
National Cancer Institute (NCI)

Not yet recruiting

Personalized Vaccine Immunotherapy in Combination With Checkpoint Inhibitor for Treatment of Triple Negative Breast Cancer

Anatomic Stage I Breast Cancer AJCC v8 | Anatomic Stage IA Breast Cancer AJCC v8 | Anatomic Stage IB Breast Cancer AJCC v8 | Anatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage IIA Breast Cancer AJCC v8 | Anatomic Stage IIB Breast Cancer AJCC v8 | Anatomic Stage III Breast Cancer AJCC v8 | Anatomic... and other conditions

United States
European Institute of Oncology

Recruiting

Vabb After Neoadjuvant Therapy to Avoid Surgery-pCR to Avoid Breast Surgery (BETTY-CRASY)

Breast Cancer | Triple Negative Breast Cancer | HER2-positive Breast Cancer | Neoadjuvant Chemotherapy

Italy
Institut Curie
Roche Pharma AG; National Research Agency, France

Not yet recruiting

Early Detection of Triple Negative Breast Cancer Relapse (CUPCAKE)

Triple Negative Breast Cancer

France
National Taiwan University Hospital
Debiopharm International SA; Ministry of Health and Welfare

Not yet recruiting

Neoadjuvant Chemotherapy With or Without GnRH Agonist for Premenopausal Triple-negative Early Breast Cancer Patients (ESCALATE)

Triple Negative Breast Cancer | Premenopausal Breast Cancer
CytosinLab Therapeutics Co., Ltd.

Recruiting

CTS2190 Phase I /II Clinical Study in Patients

Pancreatic Cancer | Non-small Cell Lung Cancer | Solid Tumors | Triple-negative Breast Cancer

China
Universidad Nacional de Colombia
Fundación Salud de los Andes

Not yet recruiting

Personalized Vaccine for TNBC Immunotherapy (TEBICA003 TNBC)

Breast Cancer Female

Colombia
AstraZeneca
Daiichi Sankyo

Recruiting

A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer

Breast Cancer

United States, France, Spain, China, Italy, Australia, United Kingdom, Korea, Republic of, Vietnam, Turkey, Brazil, Japan, Taiwan, Thailand, Canada, Singapore, Mexico, Argentina, Germany, India, Philippines, Poland, South Africa
Memorial Sloan Kettering Cancer Center
Astellas Pharma US, Inc.; Corcept Therapeutics; Breast Cancer Research Foundation

Recruiting

A Study of Enzalutamide, Enzalutamide in Combination With Mifepristone, or Chemotherapy in People With Metastatic Breast Cancer

Metastatic Breast Cancer

United States
Fujian Cancer Hospital

Not yet recruiting

PARP Inhibitor CVL218 in Combination Therapy for Patients With Advanced Solid Tumors

Advanced Solid Tumor
UNICANCER
SOLTI Breast Cancer Research Group; Vall d'Hebron Institute of Oncology; MSD...

Not yet recruiting

Pembrolizumab and Chemotherapy Treatment or no Treatment Guided by the Level of TILs in Resected Early-stage TNBC (ETNA)

Triple-negative Breast Cancer
Wake Forest University Health Sciences
Merck Sharp & Dohme LLC; G1 Therapeutics, Inc.

Recruiting

Phase II Trial of Trilaciclib, Pembrolizumab, Gemcitabine and Carboplatin in Metastatic Triple-Negative Breast Cancer (ToPCourT)

Metastatic Triple-Negative Breast Cancer

United States
Myeloid Therapeutics

Recruiting

Study of MT-302 in Adults With Advanced or Metastatic Epithelial Tumors (MYE Symphony)

Epithelial Tumors, Malignant

Australia
Fudan University

Not yet recruiting

T-DXd in the First-Line Treatment of Locally Advanced or Metastatic TNBC-LAR HER2-low Patients

Triple-Negative Breast Cancer

China
Mridula George, MD

Recruiting

OCTANE: Adjuvant Liposomal Doxorubicin and Carboplatin for Early-stage Triple-negative Breast Cancer

Triple Negative Breast Cancer (TNBC)

United States
SWOG Cancer Research Network
National Cancer Institute (NCI)

Recruiting

Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer

Anatomic Stage I Breast Cancer AJCC v8 | Anatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage IIIA Breast Cancer AJCC v8 | Anatomic Stage IIIB Breast Cancer AJCC v8 | Early Stage Triple-Negative Breast Carcinoma

United States, Puerto Rico
Bangabandhu Sheikh Mujib Medical University, Dhaka...

Not yet recruiting

Effect of Platinum-based Versus Non-platinum-based Neoadjuvant Chemotherapy in Triple-negative Breast Cancer

Triple Negative Breast Cancer

Bangladesh
Shanghai Jiao Tong University School of Medicine
CSPC Ouyi Pharmaceutical Co., Ltd.; Innovent Biologics, Inc.

Not yet recruiting

Short-term Sintilimab in Combination With Taxane and Carboplatin for Neoadjuvant Therapy in Triple-negative Breast Cancer (NeoSTEP)

Triple-negative Breast Cancer
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Recruiting

Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab

Anatomic Stage I Breast Cancer AJCC v8 | Anatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage III Breast Cancer AJCC v8 | Early Stage Triple-Negative Breast Carcinoma

United States, Puerto Rico
Fudan University

Recruiting

Precise Treatment for BLIS Subtype of TNBC in the First-line Treatment of Locally Advanced or Metastatic Breast Cancer (BCTOP-T-M01)

Triple-Negative Breast Cancer

China
Fudan University

Recruiting

Famitinib in Combination With Camrelizumab and TPC in The First-line Treatment of Immunomodulatory Locally Advanced or Metastatic TNBC.

Triple-Negative Breast Cancer

China
Fudan University

Recruiting

FUSCC Refractory TNBC Platform Study (FUTURE2.0)

Triple-negative Breast Cancer

China
Vincerx Pharma, Inc.

Recruiting

Phase 1 Dose Escalation Study for VIP236 in Patients With Advanced Cancer

Neoplasms

Australia, United States
Ohio State University Comprehensive Cancer Center

Recruiting

Feasibility Study of Biobehavioral Stress Reduction Intervention in Patients With Triple Negative Breast Cancer

Anatomic Stage I Breast Cancer AJCC v8 | Anatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage III Breast Cancer AJCC v8 | Triple-Negative Breast Carcinoma | HER2-Negative Breast Carcinoma | Hormone Receptor-Negative Breast Carcinoma

United States
Fudan University

Recruiting

A Trial Exploring the Opportune Administration of Nab-paclitaxel in the First Line Treatment, Camrelizumab Combined With Nab-paclitaxel and Famitinib, of TNBC.

Triple-Negative Breast Cancer

China
AstraZeneca
SWOG Clinical Trials Partnerships; Daiichi Sankyo

Recruiting

A Study of Dato-DXd With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Breast03)

Breast Cancer

United States, China, Denmark, United Kingdom, Korea, Republic of, Canada, Germany, Italy, Belgium, Spain, Japan, France, Taiwan, Greece, Brazil, Sweden, Puerto Rico
Fudan University

Recruiting

Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy (FASCINATE-N)

Breast Cancer | Breast Neoplasm | Breast Tumors | HER2-positive Breast Cancer | Locally Advanced Breast Cancer | HER2-negative Breast Cancer | Hormone Receptor Positive Tumor | Hormone Receptor Negative Tumor | Early-stage Breast Cancer | Triple-Negative Breast Cancer (TNBC)

China
Immunitas Therapeutics

Recruiting

Study of the Monoclonal Antibody IMT-009 in Patients With Advanced Solid Tumors or Lymphomas

Follicular Lymphoma | Colorectal Cancer | Hodgkin Lymphoma | Esophageal Cancer | Small Bowel Cancer | Burkitt Lymphoma | Non Small Cell Lung Cancer | Triple Negative Breast Cancer | Diffuse Large B Cell Lymphoma | Head and Neck Squamous Cell Carcinoma | Hormone Receptor Positive Breast Carcinoma | Cutaneous...

United States
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Recruiting

A Phase II Trial of Camrelizumab in Combination With Apatinib for Neoadjuvant Treatment of Early-stage TNBC With a High Proportion of TILs

Breast Cancer | Triple-Negative Breast Cancer

China
Bayer

Recruiting

A First-in-human Study to Learn How Safe the Study Drug BAY3375968, an Anti-CCR8 Antibody, is, When Given Alone or in Combination With Pembrolizumab, How it Affects the Body, How it Moves Into, Through, and Out of the Body, and to Find the Best Dose in Participants With Advanced Solid Tumors

Advanced Solid Tumors

United States, Canada, Singapore, United Kingdom, Belgium
Valo Therapeutics Oy

Recruiting

START: Safety and Anti-Tumor Activity of PeptiCRAd-1 in Treatment of Cancer

Colorectal Cancer | Non-Small Cell Lung Cancer | Melanoma (Skin) | Myxoid Liposarcoma | Synovial Sarcoma | Triple-Negative Breast Cancer

Germany
University of Washington
National Cancer Institute (NCI); University of Wisconsin, Madison

Recruiting

STEMVAC in Patients With Early Stage Triple Negative Breast Cancer

Anatomic Stage IB Breast Cancer AJCC v8 | Anatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage IIA Breast Cancer AJCC v8 | Anatomic Stage IIB Breast Cancer AJCC v8 | Anatomic Stage III Breast Cancer AJCC v8 | Anatomic Stage IIIA Breast Cancer AJCC v8 | Anatomic Stage IIIB Breast Cancer AJCC... and other conditions

United States
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

Recruiting

SKB264 +/- KL-A167 in Recurrent or Metastatic HER2-negative Breast Cancer

Triple-negative Breast Cancer and HR+/HER2- BC

China
Fudan University

Not yet recruiting

A Clinical Study of the Efficacy and Safety of Chidamide in Combination With Camrelizumab and Carboplatin or Capecitabine in the Second and Third Line Treatment of Relapsed/Metastatic Triple-negative Breast Cancer

Triple-negative Breast Cancer

China
AstraZeneca
Daiichi Sankyo

Recruiting

A Study of Dato-DXd Versus Investigator's Choice Chemotherapy in Patients With Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer, Who Are Not Candidates for PD-1/PD-L1 Inhibitor Therapy (TROPION-Breast02)

Breast Cancer

United States, Spain, United Kingdom, Korea, Republic of, Philippines, Canada, Germany, Italy, Poland, Belgium, Mexico, Japan, France, Brazil, Taiwan, Thailand, Hungary, Turkey, China, India, South Africa, Singapore, Argentina
Chipscreen Biosciences, Ltd.

Recruiting

A Phase II Study of Chiauranib in Combine With Capecitabine in TNBC

Triple-negative Breast Cancer

China
Amgen

Recruiting

A Study Evaluating Bemarituzumab in Solid Tumors With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression (FORTITUDE-301)

Solid Tumors

Canada, Korea, Republic of, Australia, Netherlands, United States, Israel, Austria, Spain, United Kingdom, France, Belgium, Japan, Czechia, Hungary, Poland, Brazil, Italy, Argentina, Denmark, Greece, Mexico, Switzerland, Romania, Finland and more
Mayo Clinic

Recruiting

Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors (PNeoVCA)

Metastatic Renal Cell Carcinoma | Anatomic Stage III Breast Cancer AJCC v8 | Anatomic Stage IIIA Breast Cancer AJCC v8 | Anatomic Stage IIIB Breast Cancer AJCC v8 | Anatomic Stage IIIC Breast Cancer AJCC v8 | Prognostic Stage III Breast Cancer AJCC v8 | Prognostic Stage IIIA Breast Cancer AJCC v8 and other conditions

United States
Nuvation Bio Inc.

Recruiting

NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors

Breast Cancer | Pancreatic Cancer | Ovarian Cancer | Prostate Cancer | Breast Carcinoma | Triple Negative Breast Cancer | Triple Negative Breast Neoplasms | Advanced Solid Tumor | Cancer of the Ovary | Pancreas Cancer | Triple-negative Breast Cancer | Cancer of Pancreas | Pancreas Neoplasm | Prostate Neoplasm | Cancer... and other conditions

United States, Australia
TScan Therapeutics, Inc.

Recruiting

A Tissue Collection Study in Patients Who Respond to Immune Checkpoint Inhibitors to Identify Targets of Tumor-Reactive T Cells.

Solid Tumor, Adult

United States
Seagen Inc.

Recruiting

A Study of SGN-B7H4V in Advanced Solid Tumors

Carcinoma, Non-Small-Cell Lung | Adenoid Cystic Carcinoma | Ovarian Neoplasms | Fallopian Tube Neoplasms | Peritoneal Neoplasms | Endometrial Neoplasms | Cholangiocarcinoma | Triple Negative Breast Neoplasms | Gallbladder Carcinoma | HER2 Negative Breast Neoplasms | Hormone Receptor Positive Breast Neoplasms

United States, Spain, Canada, United Kingdom, Germany, Italy

Search clinical trials for: Triple-negative Breast Cancer

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Ukraine

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations